Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study
- PMID: 27756910
- DOI: 10.1038/ja.2016.124
Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study
Abstract
The purpose of this study was to validate the mutant selection window (MSW) hypothesis in vitro and in vivo with Escherichia coli and Pseudomonas aeruginosa exposed to fosfomycin. Two standard strains of Gram-negative bacteria, those are E. coli ATCC 25922 and P. aeruginosa ATCC 27853, were exposed to fosfomycin at concentrations below MIC, between the MIC and the mutant prevention concentration (MPC), and above the MPC in Luria-Bertani broth and in a tissue-cage infection model, respectively. With the in vitro time-kill studies, there were bacterial re-growth and emergence of resistance thereafter for both strains at antibiotic concentrations of × 4, × 8 and × 16 MIC. In our animal model, the loss in susceptibility of P. aeruginosa at fosfomycin concentrations fluctuated between the lower and upper boundaries of the MSW. In contrast, the emergence of resistant mutants of E. coli was not observed in vivo, regardless of fosfomycin dosage. Interestingly, the in vitro-isolated resistant mutants of E. coli showed a decreased growth rate compared with the susceptible parental strains, whereas no fitness cost in P. aeruginosa was observed. The emergence of antibiotic resistance is shaped by several factors. MSW theory may not apply to all antimicrobial-pathogen combinations. Before it can be used as a framework for the design of antimicrobial therapy, the existence of the window must be demonstrated not only in vitro but also in vivo.
Similar articles
-
Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):737-44. doi: 10.1007/s10096-014-2285-6. Epub 2014 Nov 26. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25424036
-
In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.BMC Vet Res. 2014 Dec 16;10:297. doi: 10.1186/s12917-014-0297-1. BMC Vet Res. 2014. PMID: 25511985 Free PMC article.
-
Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.J Antimicrob Chemother. 2016 Mar;71(3):678-84. doi: 10.1093/jac/dkv387. Epub 2015 Nov 30. J Antimicrob Chemother. 2016. PMID: 26626718
-
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.J Antimicrob Chemother. 2012 Feb;67(2):255-68. doi: 10.1093/jac/dkr466. Epub 2011 Nov 16. J Antimicrob Chemother. 2012. PMID: 22096042 Review.
-
Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales.Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0144621. doi: 10.1128/AAC.01446-21. Epub 2021 Nov 22. Antimicrob Agents Chemother. 2022. PMID: 34807759 Free PMC article. Review.
Cited by
-
Halicin: A New Horizon in Antibacterial Therapy against Veterinary Pathogens.Antibiotics (Basel). 2024 May 27;13(6):492. doi: 10.3390/antibiotics13060492. Antibiotics (Basel). 2024. PMID: 38927159 Free PMC article.
-
Fosfomycin in antimicrobial stewardship programs.Rev Esp Quimioter. 2019 May;32 Suppl 1(Suppl 1):62-66. Rev Esp Quimioter. 2019. PMID: 31131594 Free PMC article. Review.
-
In Vitro Antibacterial Activities of Fosfomycin against Escherichia coli Isolates from Canine Urinary Tract Infection.Animals (Basel). 2024 Jun 28;14(13):1916. doi: 10.3390/ani14131916. Animals (Basel). 2024. PMID: 38998027 Free PMC article.
-
Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.Can J Infect Dis Med Microbiol. 2018 Jun 25;2018:8912039. doi: 10.1155/2018/8912039. eCollection 2018. Can J Infect Dis Med Microbiol. 2018. PMID: 30046362 Free PMC article. Review.
-
Evaluation of the mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in an in vitro dynamic model.Front Vet Sci. 2023 Jan 30;10:1107608. doi: 10.3389/fvets.2023.1107608. eCollection 2023. Front Vet Sci. 2023. PMID: 36793382 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases